LLY

912.18

+0.56%↑

UNH

577.78

-0.27%↓

NVO

134.8

+1.94%↑

JNJ

165.28

-0.97%↓

ABBV

193.3

-0.33%↓

LLY

912.18

+0.56%↑

UNH

577.78

-0.27%↓

NVO

134.8

+1.94%↑

JNJ

165.28

-0.97%↓

ABBV

193.3

-0.33%↓

LLY

912.18

+0.56%↑

UNH

577.78

-0.27%↓

NVO

134.8

+1.94%↑

JNJ

165.28

-0.97%↓

ABBV

193.3

-0.33%↓

LLY

912.18

+0.56%↑

UNH

577.78

-0.27%↓

NVO

134.8

+1.94%↑

JNJ

165.28

-0.97%↓

ABBV

193.3

-0.33%↓

LLY

912.18

+0.56%↑

UNH

577.78

-0.27%↓

NVO

134.8

+1.94%↑

JNJ

165.28

-0.97%↓

ABBV

193.3

-0.33%↓

Accueil・Liste d'Actions・BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals Inc

Ouvert

Secteur Soins de santé

8.15 2.77

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

7.91

Max

8.24

Chiffres clés
By Trading Economics
BPA	-0.172
Marge bénéficiaire	-66.092
Employés	536

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+92.59 upside

Dividendes
By Dow Jones
Prochains Résultats	31 oct. 2024

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	41M 990M
Ouverture précédente	5.38
Clôture précédente	8.15

Sentiment de l'Actualité

By Acuity

29%

71%

65 / 366 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Weak Bullish Evidence

6.1 / 7.65 Support & Résistance

BioCryst Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

18 sept. 2024, 23:48 UTC

Actualités

Republican Divisions Sink House Bill as Government Shutdown Nears -- Update

18 sept. 2024, 22:50 UTC

Actualités

Republican Divisions Sink House Bill as Government Shutdown Nears -- WSJ

18 sept. 2024, 22:46 UTC

Actualités

Boeing Furloughs White-Collar Workers as Strike Worsens Cash Crunch -- 2nd Update

18 sept. 2024, 22:03 UTC

Actualités

Fed Cuts Rates by Half Percentage Point -- 6th Update -2-

18 sept. 2024, 22:03 UTC

Actualités

Fed Cuts Rates by Half Percentage Point -- 6th Update

18 sept. 2024, 21:59 UTC

Actualités

AT&T Will Remove Lead Cables From Lake Tahoe -- WSJ

18 sept. 2024, 21:44 UTC

Actualités

GameStop CEO Cohen to Pay Nearly $1M for Alleged Wells Fargo Securities-Acquisition Violation -- Update

18 sept. 2024, 21:02 UTC

Market Talk

Global Equities Roundup: Market Talk

18 sept. 2024, 21:02 UTC

Market Talk

T-Mobile Capital Plan Keeps Its Options Open -- Market Talk

18 sept. 2024, 20:50 UTC

Market Talk

Acquisitions, Fusions, Rachats

Tech, Media & Telecom Roundup: Market Talk

18 sept. 2024, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

18 sept. 2024, 20:33 UTC

Actualités

Stocks Slip After Fed Cuts Rates -- WSJ

18 sept. 2024, 20:14 UTC

Market Talk

Bank of Canada Minutes Reveal Consideration of Faster Rate-Cutting Cycle -- Market Talk

18 sept. 2024, 20:07 UTC

Actualités

U.S. Stocks Pull Back After Fed Rate Cut -- WSJ

18 sept. 2024, 19:27 UTC

Actualités

T-Mobile Strikes Deal With OpenAI -- Update

18 sept. 2024, 19:27 UTC

Market Talk

Fed's 50-Basis-Point Cut Looks To Be Pre-Emptive -- Market Talk

18 sept. 2024, 19:22 UTC

Market Talk

Crude Oil Gets Little Help From Fed Rate Cut -- Market Talk

18 sept. 2024, 19:12 UTC

Actualités

Why the Bank of England Won't Follow the Fed -- Barrons.com

18 sept. 2024, 19:10 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

18 sept. 2024, 19:10 UTC

Market Talk

Powell Shows Confidence Inflation Can Cool Without Much Jobs Loss -- Market Talk

18 sept. 2024, 19:07 UTC

Market Talk

Fed's Rate Cut To Help Emerging Market Central Banks Carry On Easing -- Market Talk

18 sept. 2024, 19:02 UTC

Market Talk

U.S. Natural Gas Futures Fall Ahead of Storage Report -- Market Talk

18 sept. 2024, 19:01 UTC

Market Talk

Fed's 50Bp Rate Cut Should Alleviate Fears Of It Being Behind Curve -- Market Talk

18 sept. 2024, 18:56 UTC

Market Talk

Treasury Yields Recover As Powell Talks About Deep Fed Cut -- Market Talk

18 sept. 2024, 18:55 UTC

Actualités

U.S. Stocks Rise After Fed Rate Reduction -- WSJ

18 sept. 2024, 18:52 UTC

Market Talk

Fed Rate Cut Gives Bank of Mexico Room to Step Up Easing -- Market Talk

18 sept. 2024, 18:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

18 sept. 2024, 18:46 UTC

Market Talk

Path Of Fed Cuts Expected To Be Moderate -- Market Talk

18 sept. 2024, 18:32 UTC

Actualités

Fed Cuts Rates by Half Percentage Point -- 5th Update

18 sept. 2024, 18:30 UTC

Market Talk

Markets Reaction to Rate Cut to Be Determined by Fedspeak -- Market Talk

Comparaison

Variation de prix

BioCryst Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

92.59% hausse

Prévisions sur 12 Mois

Moyen 15.33 USD 92.59%

Haut 30 USD

Bas 7 USD

Basé sur 9 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

9 ratings

Achat

Maintien

Vente

Basé sur 9 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

6.1 / 7.65Support & Résistance

Recent bullish events outweigh bearish events.

All events are bullish.

All events are bearish.

Sentiment

By Acuity

65 / 366Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc. discovers oral and small-molecule medicines that treat rare diseases in which unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease. ORLADEYO (berotralstat) is an oral, once-daily therapy that is approved in the United States, the European Union, Japan, and the United Kingdom for the prevention of hereditary angioedema attacks in adults and pediatric patients 12 years and older. The Company has several ongoing development programs, including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases; BCX9250, an activin receptor-like kinase-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, an antiviral drug for Marburg virus disease and Yellow Fever. RAPIVAB (peramivir injection) is a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the United States, Canada, Australia, Japan, Taiwan and Korea.